De novo donor specific antibodies and patient outcomes in renal transplantation.

J. M. DeVos, S. J. Patel, K. M. Burns, S. Dilioglou, L. W. Gaber, R. J. Knight, A. O. Gaber, Geoffrey Land

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Single antigen identification of HLA antibodies is used to detect donor specific antibodies (DSAs). However, the impact of DSA elements such as class, relative strength, duration, and longitudinal effect on graft function and survival, remains unclear. Routine DSAs (LabScreen, One Lambda, Inc., Canoga Park, CA) and metabolic studies were performed at 1, 3, 6, 9, and 12 months post-transplant, and every 6 months for renal transplant recipients from 7/2007-7/2010 (n = 389). Biopsies were evaluated by updated Banff 2005 guidelines after two consecutive positive DSAs. Based on these tests, 25% of recipients developed de novo DSA. Those with DSA had increased acute rejection episodes (AR), higher creatinine (Scr), and worse graft survival. Three subgroups of these patients were identified based on duration: persistent DSA (> 1), isolated DSA, or no DSA. Persistent DSA patients were more likely to be African American, and have higher mean fluorescence intensity (MFI) and AR rates. Persistent DSA patients, with or without AR, had elevated Scr. Recipients with DQ-only DSA had higher rates of antibody mediated rejection (AMR). From this, we conclude that routine posttransplant DSA monitoring identifies recipients at risk for graft damage or loss. Persistent de novo DSAs correlated with inferior graft outcomes and AMR. With or without AR, DSA persistence was associated with worse outcomes, possibly warranting intervention. De novo DQ-DSA may be a biomarker for chronic damage and/or AMR, while an isolated DSA determination appears clinically insignificant.

Original languageEnglish (US)
Pages (from-to)351-358
Number of pages8
JournalClinical transplants
StatePublished - Jan 1 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'De novo donor specific antibodies and patient outcomes in renal transplantation.'. Together they form a unique fingerprint.

Cite this